实用肿瘤学杂志 ›› 2012, Vol. 26 ›› Issue (4): 369-372.doi: 10.3969/j.issn.1002-3070.2012.04.019

• 综述 • 上一篇    下一篇

髓源性抑制细胞——肿瘤免疫治疗的新靶点

武丽华1, 王东亮1, 张艳桥1, 2   

  1. 1.哈尔滨医科大学附属第三医院内八科(哈尔滨 150081);
    2.哈尔滨医科大学肿瘤防治研究所
  • 收稿日期:2012-02-23 出版日期:2012-08-28 发布日期:2014-12-03
  • 通讯作者: 张艳桥,E-mail:yanqiaozhang@126.com
  • 作者简介:武丽华,女,(1984-),硕士在读,从事消化道肿瘤的化疗、分子靶向治疗及生物治疗

Myeloid-derived suppressor cells:a new target of cancer immunotherapy

WU Lihua1,WANG Dongliang1,ZHANG Yanqiao1,2   

  1. 1.Department of Internal Medicine,The Third Affiliated Hospital of Harbin Medical University,Harbin 150081;
    2.The cancer Institute of Harbin Medical University,Harbin 150081
  • Received:2012-02-23 Online:2012-08-28 Published:2014-12-03

摘要: 髓源性抑制细胞(Myeloid-derived suppressor cells,MDSCs)是在病理情况下扩增的一种髓源性抑制细胞群,其特点是能负向调节机体的抗肿瘤免疫反应从而促进肿瘤的发生和发展。通过阻断MDSCs的免疫抑制通路来提高肿瘤免疫治疗的效果,是一个颇有前景的治疗策略。

Abstract: Myeloid-derived suppressor cells(MDSCs)are a heterogeneous population of myeloid derived cells Which were amplified in pathological status,which is characterized as negatively regulating the anti-tumor immune response with the result of promoting tumorigenesis and cancer development.It is a promising strategy to enhance the effect of cancer immunotherapy through blocking the immunosuppressive pathway of MDSCs.

中图分类号: